PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability

Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Munari, Enrico, Zamboni, Giuseppe, Marconi, Marcella, Sommaggio, Marco, Brunelli, Matteo, Martignoni, Guido, Netto, George J., Moretta, Francesca, Mingari, Maria Cristina, Salgarello, Matteo, Terzi, Alberto, Picece, Vincenzo, Pomari, Carlo, Lunardi, Gianluigi, Cavazza, Alberto, Rossi, Giulio, Moretta, Lorenzo, Bogina, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685736/
https://www.ncbi.nlm.nih.gov/pubmed/29163815
http://dx.doi.org/10.18632/oncotarget.21485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685736/
https://www.ncbi.nlm.nih.gov/pubmed/29163815
http://dx.doi.org/10.18632/oncotarget.21485

Ejemplares similares